REVIEW: Transitioning Adolescents With Inflammatory Bowel Diseases to Adult Care

Adolescents and young adults diagnosed with inflammatory bowel diseases (IBDs) in pediatric care are vulnerable during their transition to adult care. A review article in the February issue of Clinical Gastroenterology and Hepatology discusses the transition from pediatric to adult care for IBD, makes recommendations to improve this process, and identifies

Read more
  • AGA Clinical Practice Guideline: Management of Moderate to Severe Ulcerative Colitis

AGA Clinical Practice Guideline: Management of Moderate to Severe Ulcerative Colitis

The AGA’s latest guideline provides recommendations for the management of adult outpatients with moderate to severe ulcerative colitis (UC) and adult hospitalized patients with acute severe UC. The guideline, written by Joseph D. Feuerstein et al, discusses the use of immunomodulators, biologics, and small molecules to induce and maintain remission

Read more
  • How Is The Intestinal Microbiome Altered in Patients With IBD and Does it Change During Therapy?

How Is The Intestinal Microbiome Altered in Patients With IBD and Does it Change During Therapy?

Treatment of inflammatory bowel diseases (IBD) with anti-tumor necrosis factor (anti-TNF) drugs restores diversity to the intestinal microbiome, researchers report in the November issue of Gastroenterology.  The study associates metabolic interactions among luminal bacteria with outcomes of therapy. Altered interactions between the mucosal immune system and intestinal microbiota contribute to

Read more
  • IBD Research Highlights from 2019 ECCO Congress

IBD Research Highlights from 2019 ECCO Congress

A variety of exciting findings from inflammatory bowel disease (IBD) research were presented at the Congress of the European Crohn’s and Colitis Organisation (ECCO), held in Copenhagen, March 7–9. Shixian Hu (Universitair Medisch Centrum Groningen, The Netherlands) reported on associations between genetic factors and the microbiome in patients with IBD.

Read more
  • What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

Despite advances in methods of clinical trials for ulcerative colitis (UC), there is still a large amount of variation in endpoints, even in definitions of response and remission, reseachers found in a systematic review published in the May issue of Clinical Gastroenterology and Hepatology. The authors conclude that we need a

Read more